Retroviral vectors as vaccines and immunotherapeutics. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Retroviral vectors as vaccines and immunotherapeutics.

Semin Immunol. 1990 Sep;2(5):329-39. Unique Identifier : AIDSLINE MED/92182248
Jolly DJ; Warner JF; Viagene Inc, San Diego, CA 92121.

Abstract: Retroviral vectors have been tested in mice for their ability to induce immune response to the proteins which their genomes encode. Using HIV encoded proteins as a model, potent cytotoxic T lymphocyte (CTL) and antibody responses are seen to these proteins. This apparent efficacy of induction may be due to the relative simplicity of the vector and the manner in which antigens are presented to the immune system. Safety issues and other proposed methods of CTL induction are discussed. The potential application of retroviral vectors as immune stimuli in man seems quite broad (viral diseases and cancer), and the first attempted applications in man are likely to be therapeutic rather than prophylactic.
Keywords: Genetic Vectors/*IMMUNOLOGY Human HIV Antigens/IMMUNOLOGY HIV Infections/PREVENTION & CONTROL Immunity, Cellular *Immunotherapy, Active Leukemia Viruses, Murine/GENETICS/IMMUNOLOGY Models, Biological Recombinant Fusion Proteins/GENETICS/*IMMUNOLOGY Retroviridae/GENETICS/*IMMUNOLOGY Support, Non-U.S. Gov't Vaccines, Synthetic/GENETICS/*IMMUNOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDgeneticvectors/KWDimmunologyhumanhivantigens/immunologyhivinfections/prevention&controlimmunity,cellularKWDimmunotherapy,activeleukemiaviruses,murine/genetics/immunologymodels,biologicalrecombinantfusionproteins/genetics/KWDimmunologyretroviridae/genetics/KWDimmunologysupport,non-uKWDsKWDgov'tvaccines,synthetic/genetics/KWDimmunologyjournalarticlereviewreview,tutorial
920630
M9260992

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .